Biosimilars in Dermatology - theory becomes reality.

@article{Gerdes2018BiosimilarsID,
  title={Biosimilars in Dermatology - theory becomes reality.},
  author={Sascha Gerdes and Ulrich Mrowietz and Matthias Augustin and Ralph von Kiedrowski and Alexander H Enk and Klaus Stroemer and Michael P Sch{\"o}n and Marc A Radtke},
  journal={Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG},
  year={2018},
  volume={16 2},
  pages={
          150-160
        }
}
Biosimilars are biological medicines that are analogues of a specific reference product. Biosimilars of the tumor necrosis factor alpha inhibitors infliximab and etanercept are already approved and available for dermatological indications. Regulatory agencies require in-depth analysis of physicochemical and functional properties of these highly complex molecules as well as clinical data on their similarity regarding efficacy and safety in at least one clinical trial in a sensitive and… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…